Home › Crohn's Disease › Colorado
Crohn's Disease clinical trials in Colorado
18 studies for Crohn's Disease are looking for participants at sites in Colorado.
Cities in Colorado
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 5026), Aurora
- Peak Gastroenterology Associates ( Site 5023), Colorado Springs
- South Denver Gastroenterology, PC ( Site 5132), Englewood
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 280507, Colorado Springs
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Peak Gastroenterology Associates, Colorado Springs
- Rocky Mountain Endocopy Centers LLC, Littleton
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 265557, Colorado Springs
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UCHealth Digestive Health Center - Anschutz Medical Campus-Site Number: 8400085, Aurora
- Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado Springs
- Gastroenterology of the Rockies - Denver-Site Number: 8400122, Denver
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado Springs
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Children's Hospital Colorado - Aurora /ID# 255764, Aurora
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates - Colorado Springs, Colorado Springs
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 22, 2026 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- South Denver Gastroenterology, Englewood
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- South Denver Gastroenterology, Englewood
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483099A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577843Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Colorado, Aurora
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Children's Hospital Colorado - Aurora /ID# 262207, Aurora
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated May 27, 2026 · NCT06227910Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Peak Gastroenterology Associates, Colorado Springs
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Colorado Springs
- Mirador Therapeutics Selected Site, Littleton
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.